As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

New York-based Jones just raised $10 million to expand its nicotine lozenge company in the stodgy, $3 billion smoking cessation market.

Minoxidil is best known as the key ingredient in Rogaine, the popular hair loss solution launched more than 30 years ago.

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Patients taking compounded weight loss drugs from online pharmacies share what it's like — and they couldn't go the ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Hims & Hers Health stock corrected after earnings because of the outlook on its key GLP-1 medication. See why I rate HIMS a ...

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...